Ezz Life Science Holdings Ltd. · ASX:EZZ
Ezz Life Science — FY2023 Earnings Presentation
17 slides from Ezz Life Science's earnings presentation, Aug 29, 2023
Slide 1: FY23 (unaudited) Results Presentation
Our mission is to improve quality of life and human health. FY23 (unaudited) Results Presentation Glenn Cross, Non-Executive Director and Chair Tony Guarna, Chief Financial Officer
Slide 2: Disclaimer
DISCLAIMER This document has been prepared by EZZ Life Science Holdings Limited ACN 608 363 604 (Company). By accepting a copy of this document you warrant and undertake to the Company that you agree to be bound by the terms and conditions set out below. This document is not a prospectus, product di
Slide 3: Contents
Contents FY23 Highlights FY23 Financial Performance Strategy Outlook for FY24 Q&A
Slide 4: FY23 Highlights
FY23 Highlights New Distribution Strong Financial Channels and New Product Performance Geographical Development Markets Strong revenue growth of Eighteen new products 147.3% from $15m last year Strong growth on the Douyin under its own brand and to $37.1m in FY23. platform (launched Q4 FY22) distrib
Slide 5: FY23 Operational Overview
FY23 Operational Overview Research and Development Channel Diversification Market Exposure 18 new products 5 new channels 4 International Expos under the EZZ brand added to e-commerce strategies expansion strategy Revenue from Revenue from Revenue from the Best-Selling Product the Best Performing Ch
Slide 6: Our Products
Our Products We formulate, produce, market and distribute health supplements under We are an exclusive wholesale distributor of skin care products under the the brand of EZZ. Our deep understanding of our target consumers EAORON brand in Australia and New Zealand to pharmacies, allows us to develop
Slide 7: FY23 Financial Overview
FY23 Financial Overview Cash on Hand Revenue EBITDA $37.1M $5.1M $13.8M Up by 32.2% from FY22 Up by 147.3% from FY22 Up by 167.7% from FY22 (No external debt) Gross Margin NPAT Interim Dividend 76.8% $3.6M $0.0098 Up from 50% in FY22 Up by 176.6% from FY22 1H FY23
Slide 8: Revenue
Revenue Record revenue growth as a result of successful market-driven R&D, dynamic channel prioritisation, and targeted B2C marketing Revenue Drivers Revenue by Segment 08
Slide 9: Margins
Margins Attractive gross margin are well maintained and improving Gross Margin 76.8% 09
Slide 10: Profitability
Profitability Solid operating profit and strong growth momentum fuelled by successful investments in marketing EBITDA (Exclude Other Income) Operating Expense Breakdown 09
Slide 11: Working Capital
Working Capital Well maintained working capital position to accelerate continuous growth Working Capital Movements 11
Slide 12: Cash Flow
Cash Flow Cash flow from operating activities more than doubled from a year ago Cash Flows Movements 12
Slide 13: Financial Position
Financial Position Equity Debt1 $13.8M $0 1 Excluding lease liabilities 10
Slide 14: Strategy
Strategy Life Science Technology People Consumers Product development pipeline to Online store and data backed Ongoing investment in people and Connection to consumers through increasingly feature healthcare analytical capability to enable data talent to support growth while omni-channel strategies
Slide 15: Outlook
Outlook • Landmark partnership with HIC with sales commencing Q1 FY24 • Gradual resumption of inbound leisure travel from China to Australia and New Zealand • Pipeline of new products • Actively exploring new geographical markets • Strong cash position to explore M&A opportunities as they arise
Slide 16: Q&A
Q&A Glenn Cross, Non-Executive Director and Chair Tony Guarna, Chief Financial Officer
Slide 17: EZZ Life Science Holdings Limited [ASX: EZZ]
EZZ LIFE SCIENCE HOLDINGS LIMITED [ASX: EZZ] EZZ Life Science Holdings Limited ABN 83 608 363 604 104 Derby Street, Silverwater NSW 2128 T: 02 9160 2305 E: ir@ezzlife.com.au EZZLifescience linkedin.com/company/ EZZAustralia EZZ_Australia www.ezzlife.com.au ezz-life-science-holdings
Ezz Life Science Holdings — FY2023 Earnings Presentation on 6ix